Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
暂无分享,去创建一个
P. Ponikowski | I. Piña | S. Kaul | G. Filippatos | S. Pocock | M. Senni | S. Anker | J. Butler | C. Wanner | M. Böhm | F. Zannad | S. Verma | B. Merkely | N. Giannetti | M. Packer | S. Janssens | H. Brunner-La Rocca | S. Nicholls | E. Bocchi | N. Sattar | J. Januzzi | S. Taddei | D. Choi | P. Carson | M. Brueckmann | H. Tsutsui | M. Séronde | V. Chopra | Jian Zhang | J. Schnee | S. Perrone | D. Cotton | I. Squire | J. Špinar | J. G. González Juanatey | W. Jamal | C. Zeller | K. Kimura | E. Chuquiure | S. Verma | M. Böhm | K. Kimura | K. Kimura
[1] S. Solomon,et al. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC Heart Failure Position Paper. , 2020, JACC. Heart failure.
[2] M. Packer. SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action , 2020, Diabetes Care.
[3] G. Filippatos,et al. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial , 2019, European journal of heart failure.
[4] Marc P. Bonaca,et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.
[5] C. Marra,et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis , 2019, BMJ Open.
[6] B. Zinman,et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial , 2018, Circulation.